BioSpace News Archive

The companies are facing questions in a criminal probe regarding their marketing distribution practices related to the sale of opioids.

Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.

There are currently three antivirals approved by the U.S. Food and Drug Administration (FDA) for genital herpes. They are acyclovir (Sitavig and Zovirax), valacyclovir (Valtrex), and famciclovir (Famvir). There are no approved vaccines.

Ultragenyx Pharmaceutical Inc. today announced that Shalini Sharp, the company’s Chief Financial Officer, will present at the Piper Jaffray 31ST Annual Healthcare Conference on Wednesday, December 4, 2019 at 2:00 PM ET in New York, NY.

NDA supported by positive interim analysis results from the Phase 3 REGENERATE study demonstrating OCA’s improvement of liver fibrosis without worsening of NASH

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, reported financial and operating results for the fourth quarter and fiscal year ended August 31, 2019 and provided a business update.

Fulgent Genetics, Inc. announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Vice President of Commercial Operations Brandon Perthuis are scheduled to participate in the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at the Lotte New York Palace Hotel in New York, New York.

HOOKIPA Pharma Inc. announced that HOOKIPA’s management team will present and host one-on-one meetings at Piper Jaffray 31st Annual Healthcare Conference, taking place December 3-5, 2019 in New York

Tetra Bio-Pharma Inc., announced that the U.S. Food and Drug Administration has authorized the advancement of Plenitude, the company’s clinical trial for its investigational therapeutic QIXLEEF™, for the treatment of uncontrolled pain in advanced cancer patients.

Patented AltuCaps® for Microencapsulation of stem cells for autoimmune and inflammatory diseases: Partnering opportunities available